Oncocyte Corporation - Common Shares, No Par Value (OCX)

CUSIP: 68235C107

Q1 2017 13F Holders as of 31 Mar 2017

Type / Class
Equity / Common Shares, No Par Value
Shares outstanding
28,495,649
Total 13F shares
3,775,245
Share change
+732,490
Total reported value
$22,466,000
Price per share
$5.94
Number of holders
25
Value change
+$4,356,561
Number of buys
15
Number of sells
4

Quarterly Holders Quick Answers

What is CUSIP 68235C107?
CUSIP 68235C107 identifies OCX - Oncocyte Corporation - Common Shares, No Par Value in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Top shareholders of OCX - Oncocyte Corporation - Common Shares, No Par Value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Holder Source Role / Reporting Ownership % Shares Holdings Value 12M Net Δ As of Details
BROADWOOD CAPITAL INC
13F
Company
9.2%
2,631,680
$18,553,000 31 Dec 2016
13F
BRIDGEWAY CAPITAL MANAGEMENT, LLC
13F
Company
0.35%
100,000
$705,000 31 Dec 2016
13F
VANGUARD GROUP INC
13F
Company
0.34%
96,878
$683,000 31 Dec 2016
13F
Manatuck Hill Partners, LLC
13F
Company
0.29%
83,958
$592,000 31 Dec 2016
13F
BlackRock Institutional Trust Company, N.A.
13F
Company
0.24%
69,217
$488,000 31 Dec 2016
13F
Artal Group S.A.
13F
Company
0.22%
64,102
$452,000 31 Dec 2016
13F
Destination Wealth Management
13F
Company
0.1%
29,656
$209,000 31 Dec 2016
13F
GEODE CAPITAL MANAGEMENT, LLC
13F
Company
0.05%
14,961
$105,000 31 Dec 2016
13F
Family Manage LLC
13F
Company
0.04%
11,950
$84,000 31 Dec 2016
13F
BlackRock Fund Advisors
13F
Company
0.04%
11,097
$78,000 31 Dec 2016
13F
PNC FINANCIAL SERVICES GROUP, INC.
13F
Company
0.01%
4,014
$28,000 31 Dec 2016
13F
MORGAN STANLEY
13F
Company
0%
1,146
$8,000 31 Dec 2016
13F
MANUFACTURERS LIFE INSURANCE COMPANY, THE
13F
Company
0%
1,050
$7,000 31 Dec 2016
13F
Carroll Financial Associates, Inc.
13F
Company
0%
850
$5,000 31 Dec 2016
13F
BlackRock Investment Management, LLC
13F
Company
0%
715
$5,000 31 Dec 2016
13F
Elgethun Capital Management
13F
Company
0%
699
$5,000 31 Dec 2016
13F
UBS Group AG
13F
Company
0%
698
$5,000 31 Dec 2016
13F
Mivtachim The Workers Social Insurance Fund Ltd. (Under Special Management)
13F
Company
0%
550
$4,000 31 Dec 2016
13F
BLACKROCK ADVISORS LLC
13F
Company
0%
478
$3,000 31 Dec 2016
13F
BANK OF AMERICA CORP /DE/
13F
Company
0%
467
$3,000 31 Dec 2016
13F
MUFG Americas Holdings Corp
13F
Company
0%
376
$3,000 31 Dec 2016
13F
Creative Planning
13F
Company
0%
265
$2,000 31 Dec 2016
13F
ROYAL BANK OF CANADA
13F
Company
0%
235
$2,000 31 Dec 2016
13F
FIFTH THIRD BANCORP
13F
Company
0%
210
$1,000 31 Dec 2016
13F
IHT Wealth Management, LLC
13F
Company
0%
100
$1,000 31 Dec 2016
13F
Harel Insurance Investments & Financial Services Ltd.
13F
Company
0%
80
$1,000 31 Dec 2016
13F

Institutional Holders of Oncocyte Corporation - Common Shares, No Par Value (OCX) as of Q1 2017

As of 31 Mar 2017, Oncocyte Corporation - Common Shares, No Par Value (OCX) was held by 25 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 3,775,245 shares. The largest 10 holders included BROADWOOD CAPITAL INC, Artal Group S.A., BRIDGEWAY CAPITAL MANAGEMENT INC, VANGUARD GROUP INC, Manatuck Hill Partners, LLC, BlackRock Inc., GOLDMAN SACHS GROUP INC, Destination Wealth Management, MILLENNIUM MANAGEMENT LLC, and Family Management Corp. This page lists 25 institutional shareholders reporting positions in this security for the Q1 2017 filing period.
Investor Option Weight % Change % Value $ * Price Shares Share Change Activity Report Period

Compare Q1 2017 vs Q4 2016 Across Filers

Q4 2016 holders
24
Q1 2017 holders
25
Holder diff
1
Investor Q4 2016 Shares Q1 2017 Shares Share Diff Share Chg % Q4 2016 Value $ Q1 2017 Value $ Value Diff $ Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.